|
|
|
|
LEADER |
04446nam a2200385 u 4500 |
001 |
EB001840226 |
003 |
EBX01000000000000001004215 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
180702 r ||| eng |
245 |
0 |
0 |
|a Diabetes (type 1 and type 2) in children and young people
|h Elektronische Ressource
|b diagnosis and management : final version
|c NCC-WCH ; commissioned by the National Institute for Health and Care Excellence
|
250 |
|
|
|a Final version 1.0
|
260 |
|
|
|a [London]
|b National Collaborating Centre for Women's and Children's Health
|c August 2015, 2015
|
300 |
|
|
|a 1 PDF file (517 pages)
|b illustrations
|
505 |
0 |
|
|a Includes bibliographical references
|
653 |
|
|
|a United Kingdom
|
653 |
|
|
|a Child
|
653 |
|
|
|a Diabetes Mellitus, Type 1 / therapy
|
653 |
|
|
|a Evidence-Based Medicine
|
653 |
|
|
|a Diabetes Mellitus, Type 2 / diagnosis
|
653 |
|
|
|a Adolescent
|
653 |
|
|
|a Diabetes Mellitus, Type 2 / therapy
|
653 |
|
|
|a Diabetes Mellitus, Type 1 / diagnosis
|
710 |
2 |
|
|a National Collaborating Centre for Women's and Children's Health (Great Britain)
|
710 |
2 |
|
|a National Institute for Health and Care Excellence (Great Britain)
|
710 |
2 |
|
|a National Collaborating Centre for Women's and Children's Health (Great Britain)
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a NICE guideline : methods, evidence and recommendations
|
500 |
|
|
|a "This guideline is a partial update of the NICE clinical guideline Type 1 diabetes: diagnosis and management of type 1 diabetes (CG15, published July 2004) and replaces the part of CG15 that relates to children and young people" --Forword. - "Update 2015."
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK315806
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a Diabetes is a long-term condition that can have a major impact on the life of a child or young person, as well as their family or carers. In addition to insulin therapy, diabetes management should include education, support and access to psychological services, as detailed here and in this guideline. Preparations should also be made for the transition from paediatric to adult services, which have a somewhat different model of care and evidence base. Type 1 diabetes is becoming more common in the UK and since 2004 type 2 diabetes has also been diagnosed with increasing frequency. The 2013 to 2014 National Diabetes Audit identified 26,500 children and young people in the UK with type 1 diabetes and 500 with type 2d. Much of the general care for type 2 diabetes is the same as for type 1 diabetes, but the initial management is different.
|
520 |
|
|
|a This national guidance is the first for children and young people to recommend attempting to reach a glycated haemoglobin (HbA1c) level in the normal range and near normoglycaemia. This tight control may be achieved by intensive insulin management (multiple daily injections or insulin pump therapy) from diagnosis, accompanied by carbohydrate counting. Newer technology, such as continuous subcutaneous glucose monitoring, may also help children and young people to have better blood glucose control, although this is not currently recommended for all children and young people with type 1 diabetes. The guideline development group believes that by implementing the strict blood glucose control recommended in this guideline, improvements can be made to diabetes care that reduce the impact of the condition on the future health of children and young people
|
520 |
|
|
|a In addition, the overweight and obesity associated with type 2 diabetes bring an increased risk of renal complications in particular, and of problems such as hypertension and dyslipidaemia. These differences in management and complications need guidance specific to type 2 diabetes, which is included here for the first time. A variety of genetic conditions (such as maturity-onset diabetes in the young) and other conditions (such as cystic fibrosis-related diabetes) may also lead to diabetes in children and young people, but the care of these diverse conditions is beyond the scope of this guideline. Since 2004 there have been major changes to the routine management of type 1 diabetes in an attempt to achieve much stricter targets for blood glucose control in order to further reduce the long-term risks associated with the condition.
|